Home › Research › Biomarkers
Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum
Lyduine Eisa Collij, Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, Tobey J. Betthauser, Olof T. Strandberg, Ruben A Smith, Sebastian Palmqvist et al.. Nature Communications, 2026-04-09
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
To efficiently implement plasma and cerebrospinal fluid (CSF) biomarkers for staging and prognosis of Alzheimer disease (AD), we must understand their dynamics across disease progression. We analyzed participants from the Swedish BioFINDER-2 study with mass spectrometry measurements of plasma and CSF tau species, including eMTBR-tau243/MTBR-tau243 and phosphorylation occupancies (%p-tau). Disease duration was estimated using Aβ-PET and tau-PET with the SILA algorithm. Bootstrapped LOESS models showed that %p-tau217 changes earliest, increasing just before Aβ-PET positivity. Other p-tau species changed later, with smaller dynamic ranges and earlier ceiling effects. %p-tau205 and MTBR-tau243 changes aligned with tau-PET positivity onset, while MTBR-tau243-especially plasma eMTBR-tau243-tracked cortical tau burden in later stages. Non-phosphorylated mid-region tau may serve as a late-stage biomarker. Taken together, concurrent assessments of plasma or CSF %p-tau217, %p-tau205, and (e)MTBR-tau243 provides information about different biological events in the disease cascade, which can benefit clinical trials and patient management in clinical practice.
What this study adds
Evidence grade: Low
This study found that %p-tau217 changes earliest in the disease process, just before amyloid PET becomes positive, while other tau markers change later and MTBR-tau243 tracks cortical tau burden in later stages. The authors say measuring these markers together provides information about different biological events in the disease cascade, which could benefit clinical trials and patient management.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Collij, L. E., Salvadó, G., Horie, K., Barthélemy, N. R., Betthauser, T. J., Strandberg, O. T., et al. (2026). Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum. Nature Communications. https://doi.org/10.1038/s41467-026-71732-1
Vancouver
Collij LE, Salvadó G, Horie K, Barthélemy NR, Betthauser TJ, Strandberg OT, et al. Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum. Nature Communications. 2026. doi:10.1038/s41467-026-71732-1. PMID: 41957377.
BibTeX
@article{collij2026-41957377,
author = {Collij, Lyduine Eisa and Salvadó, Gemma and Horie, Kanta and Barthélemy, Nicolas R. and Betthauser, Tobey J. and Strandberg, Olof T. and Smith, Ruben A and Palmqvist, Sebastian and others},
title = {{Trajectories of plasma and CSF MTBR-tau243 and phosphorylated-tau species across the Alzheimer’s disease continuum}},
journal = {Nature Communications},
year = {2026},
doi = {10.1038/s41467-026-71732-1},
pmid = {41957377},
url = {https://doi.org/10.1038/s41467-026-71732-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Bootstrapped LOESS models showed that %p-tau217 changes earliest, increasing just before Aβ-PET positivity.
- Taken together, concurrent assessments of plasma or CSF %p-tau217, %p-tau205, and (e)MTBR-tau243 provides information about different biological events in the disease cascade, which can benefit clinical trials and patient management in clinical practice.
Why it matters
This study found that %p-tau217 changes earliest in the disease process, just before amyloid PET becomes positive, while other tau markers change later and MTBR-tau243 tracks cortical tau burden in later stages. The authors say measuring these markers together provides information about different biological events in the disease cascade, which could benefit clinical trials and patient management.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 53/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 41.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41957377) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-026-71732-1
- PubMed: 41957377
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.